IV iron and EPO medicine after kidney transplant
Treatments studied
Part of Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests whether IV iron plus an “EPO-like” medicine (erythropoiesis-stimulating agent) can improve outcomes after a living-donor kidney transplant. It focuses on people with iron deficiency and measures kidney and blood recovery over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Have had a living-donor kidney transplant and be over 19 years old
- Have low iron stores: ferritin under 700 micrograms per liter
- Have low iron availability: TSAT under 40%
- Do not have active infection at the time of starting the study
- Do not have certain blood cancers or blood disorders causing anemia
- Not be HIV-positive, and avoid significant liver enzyme elevation (ALT/AST more than 3 times normal)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests two medicines (daprodustat and epoetin alfa) to see which one works better for treating low red blood cell counts (anemia) in people with chronic kidney disease who are not on dialysis yet. Both medicines aim to increase hemoglobin and reduce fatigue.
This trial is testing whether a combination of two drugs, everolimus and epoetin, can help liver transplant recipients gradually reduce their anti-rejection medicines. If successful, it may lead to long-term transplant tolerance with fewer side effects.
This trial studies whether taking iron by mouth can improve iron levels and anemia (low red blood cell counts) in children with chronic kidney disease. It may help reduce fatigue and support normal blood-making, by comparing different approaches for children who meet specific iron test results.
This trial tests whether a higher or lower dose of iron works better for people on peritoneal dialysis who have low iron levels. It aims to find the best way to treat iron deficiency in this group.
This trial tests whether a new blood test (reticulocyte hemoglobin) is better than the usual iron test (transferrin saturation) for guiding when to give iron to people on dialysis. If you have anemia (low red blood cells) from kidney disease, this study may help doctors find the best way to treat your iron levels.
This study tests whether intravenous iron can improve outcomes for people with non-ischemic heart failure and low ejection fraction who are also iron deficient. If you fit the criteria, you may receive iron infusions to see if it helps your heart function and symptoms.
Hear when a new Kidney Failure, Chronic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.